Idorsia Pharmaceuticals
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Idorsia Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#484 of 15,742 sponsors by registered trial count).
Idorsia Pharmaceuticals: 34 sponsored US clinical trials, 1 recruiting.
Idorsia Pharmaceuticals sponsors 34 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 27 completed. 14 of these trials are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Insomnia Disorder, with 3 trials.
Top-decile sponsor footprint
Idorsia Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#484 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
27 of 31 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
34 total, page 1 of 1
Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®
NCT06498128
Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)
NCT06393504
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease
NCT03737214
A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants
NCT05877222
A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia
NCT05597020
A Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women
NCT05632393
Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder
NCT05423717
Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder
NCT04753164
Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2
NCT04470713
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects
NCT03869320
Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain
NCT03585270
Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep
NCT03679884
Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users
NCT03657355
A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects
NCT03586570
Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease
NCT03425539
A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety
NCT03541174
Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder
NCT03545191
Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep
NCT03575104
Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia Disorder
NCT03056053
Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder
NCT02841709
Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder
NCT02839200
A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects
NCT02841761
Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
NCT02603809
Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis
NCT01484119
Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma
NCT01225315
Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis
NCT01241214
Tezosentan in Patients With Pulmonary Arterial Hypertension
NCT01094067
Tezosentan in Pulmonary Arterial Hypertension
NCT01077297
Clazosentan in Aneurysmal Subarachnoid Hemorrhage
NCT00940095
Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping
NCT00558311
Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery
NCT00458276
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
NCT00111085
Tezosentan in Acute Heart Failure
NCT00525707
Tezosentan in the Treatment of Acute Heart Failure
NCT00524433
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 11 |
| Phase 3 | 13 |
| Phase 4 | 1 |
What is open in the Idorsia Pharmaceuticals pipeline
1 recruiting of 34 indexed (3% open); 27 completed (79%).
Phase mix: 14 late (III/IV) vs 17 early (I/II) (balanced across stages).
Top condition: Insomnia Disorder (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Idorsia Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 34 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Idorsia Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 34 trials (± recruiting share)
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · 34 trials · 38% recruiting
- American Regent · 34 trials · 0% recruiting
- Amicus Therapeutics · 34 trials · 15% recruiting
- Cochlear · 34 trials · 12% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Klein Buendel · 3% recruiting · 34 trials
- Kyowa Kirin · 3% recruiting · 34 trials
- National Center for Complementary and Integrative Health (NCCIH) · 3% recruiting · 203 trials
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · 3% recruiting · 138 trials
Related
What to do with this Idorsia Pharmaceuticals page
34 registered trials is a research-attention snapshot, not an endorsement of Idorsia Pharmaceuticals or any single study.
- 1 of Idorsia Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Insomnia Disorder is the condition Idorsia Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Insomnia Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Idorsia Pharmaceuticals pipeline card: 34 registered trials from official public datasets.Report a data error.